1,163 Shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC) Purchased by Mather Group LLC.

Mather Group LLC. purchased a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,163 shares of the company’s stock, valued at approximately $106,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital Research Global Investors boosted its stake in GE HealthCare Technologies by 2.8% during the fourth quarter. Capital Research Global Investors now owns 51,344,719 shares of the company’s stock valued at $3,969,975,000 after buying an additional 1,401,566 shares during the last quarter. Vanguard Group Inc. boosted its stake in GE HealthCare Technologies by 14.7% during the third quarter. Vanguard Group Inc. now owns 44,531,402 shares of the company’s stock valued at $3,029,917,000 after buying an additional 5,693,244 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its stake in GE HealthCare Technologies by 9.4% during the fourth quarter. Hotchkis & Wiley Capital Management LLC now owns 5,511,973 shares of the company’s stock valued at $426,186,000 after buying an additional 471,910 shares during the last quarter. Northern Trust Corp boosted its stake in GE HealthCare Technologies by 8.9% during the third quarter. Northern Trust Corp now owns 4,205,506 shares of the company’s stock valued at $286,143,000 after buying an additional 342,040 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in GE HealthCare Technologies by 17.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,454,690 shares of the company’s stock valued at $267,121,000 after buying an additional 504,287 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Frank R. Jimenez acquired 1,315 shares of GE HealthCare Technologies stock in a transaction on Wednesday, May 1st. The shares were bought at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the acquisition, the insider now directly owns 75,796 shares of the company’s stock, valued at approximately $5,799,909.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Frank R. Jimenez purchased 1,315 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were acquired at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the acquisition, the insider now owns 75,796 shares of the company’s stock, valued at approximately $5,799,909.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CTO Taha Kass-Hout sold 3,300 shares of GE HealthCare Technologies stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the completion of the transaction, the chief technology officer now owns 67,300 shares in the company, valued at $5,296,510. The disclosure for this sale can be found here. Insiders have sold 90,482 shares of company stock worth $7,369,137 in the last ninety days. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Citigroup raised their price objective on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Argus raised their price objective on GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Mizuho lowered their price objective on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. The Goldman Sachs Group assumed coverage on GE HealthCare Technologies in a research note on Thursday, May 30th. They issued a “neutral” rating and a $87.00 price objective for the company. Finally, Evercore ISI raised their price objective on GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.09.

GE HealthCare Technologies Trading Down 0.3 %

Shares of NASDAQ GEHC opened at $79.17 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06. The business’s 50 day moving average price is $80.68 and its 200-day moving average price is $81.32. GE HealthCare Technologies Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $94.50. The company has a market cap of $36.14 billion, a price-to-earnings ratio of 23.15, a PEG ratio of 2.81 and a beta of 1.22.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, hitting the consensus estimate of $0.90. The company had revenue of $4.65 billion for the quarter, compared to the consensus estimate of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. GE HealthCare Technologies’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the business posted $0.85 EPS. On average, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.